Trial Profile

Anti-CD7 Universal CAR-T Cells for CD7+ T/NK Cell Hematologic Malignancies: a Multi-center, Uncontrolled Trial

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 29 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GC 027 (Primary) ; Cyclophosphamide; Fludarabine; Melphalan
Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Extranodal NK-T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma; Sezary syndrome
Focus Therapeutic Use

Most Recent Events

21 Jun 2021 Planned End Date changed from 1 Apr 2022 to 1 Jun 2023.
21 Jun 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Jun 2022.
21 Jun 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com